Send us a text

Anesthesiologist Dr. Todd Bertoch speaks with Dr. Michael Koren in this exciting episode about the a new pain medication, Journavx (suzetrigine), which was just approved by the FDA in January, 2025. The doctors discuss this breakthrough pain management medication, its safety profile, side effects, and how it compares to NSAIDs, acetaminophen, and opioids. They also dive into the approval process, how trials were conducted and standardized, and where the medication will go from here.

Koren's Key Takeaways:

• New options like suzetrigine for pain medication that are non-addicting are needed
• This medication is another tool, not a replacement for opioids
• The clinical trials for this medication have been rigorous

Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at [email protected]

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!